BeiGene, Ltd.
BeiGene, Ltd. Fundamental Analysis
BeiGene, Ltd. (BGNE) shows weak financial fundamentals with a PE ratio of 296.98, profit margin of 1.38%, and ROE of 1.86%. The company generates $4.9B in annual revenue with strong year-over-year growth of 54.96%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 57.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze BGNE's fundamental strength across five key dimensions:
Efficiency Score
WeakBGNE struggles to generate sufficient returns from assets.
Valuation Score
ModerateBGNE shows balanced valuation metrics.
Growth Score
ExcellentBGNE delivers strong and consistent growth momentum.
Financial Health Score
ExcellentBGNE maintains a strong and stable balance sheet.
Profitability Score
ModerateBGNE maintains healthy but balanced margins.
Key Financial Metrics
Is BGNE Expensive or Cheap?
P/E Ratio
BGNE trades at 296.98 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BGNE's PEG of 1.56 indicates fair valuation.
Price to Book
The market values BeiGene, Ltd. at 4.93 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 91.35 times EBITDA. This signals the market has high growth expectations.
How Well Does BGNE Make Money?
Net Profit Margin
For every $100 in sales, BeiGene, Ltd. keeps $1.38 as profit after all expenses.
Operating Margin
Core operations generate 3.67 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.86 in profit for every $100 of shareholder equity.
ROA
BeiGene, Ltd. generates $0.90 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BeiGene, Ltd. produces operating cash flow of $779.65M, showing steady but balanced cash generation.
Free Cash Flow
BeiGene, Ltd. generates strong free cash flow of $540.62M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $4.94 in free cash annually.
FCF Yield
BGNE converts 2.69% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
296.98
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.56
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.93
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.06
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.25
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.39
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.009
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How BGNE Stacks Against Its Sector Peers
| Metric | BGNE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 296.98 | 29.43 | Worse (Expensive) |
| ROE | 1.86% | 800.00% | Weak |
| Net Margin | 1.38% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.25 | 0.30 | Neutral |
| Current Ratio | 2.39 | 4.64 | Strong Liquidity |
| ROA | 0.90% | -17936.00% (disorted) | Weak |
BGNE outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BeiGene, Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
410.38%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
61.09%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
89.25%
Industry Style: Defensive, Growth, Innovation
High Growth